غربالگری پلی مورفیسم جایگاه Phe80Val ژن MLH1 در زنان مبتلا به سرطان تخمدان با تکنیک Tetra ARMS-PCR
محورهای موضوعی : نشانگر های زیستی پلاسما
1 - گروه ژنتیک، واحد تنکابن، دانشگاه آزاد اسلامی، تنکابن، ایران
کلید واژه: سرطان تخمدان, پروموتر, بیان ژن MLH1,
چکیده مقاله :
زمینه و هدف: ﺳﺮﻃﺎن اﭘﯽﺗﻠﯿﺎل ﺗﺨﻤﺪان 90% ﺑﺪﺧﯿﻤﯽ ﻫﺎي ﺗﺨﻤﺪان و 25% ﺑﺪﺧﯿﻤﯽﻫﺎي ﺗﻨﺎﺳـﻠﯽ زﻧﺎن را ﺗﺸﮑﯿﻞ ﻣﯽدﻫﺪ و از آﻧﺠﺎ ﮐﻪ دﯾـرتشخیص داده می شود،ﺑﻪ ﻫﻤﯿﻦ دﻟﯿﻞ در ﺑﯿﻦ همه ی ﺑﺪﺧﯿﻤﯽ ﻫﺎي دﺳﺘﮕﺎه ﺗﻨﺎﺳﻠﯽ زﻧـﺎن از ﺑـﺎﻻﺗﺮﯾﻦ ﻣﻮارد ﻣﺮگ وﻣﯿﺮ ﺑﺮﺧﻮردار اﺳت. ﺗﻐﯿﯿﺮات ریزRNA که بیان ژن را کنترل میکند در این سرطان به چشم می خورد. تغییر در الگوی متیله شدن در ناحیه پروموتر ژن ها نیز از دیگر پیشامد های سرطان تخمدان است.
مواد و روش ها: در مطالعه حاضر نمونه های مورد آزمايش افراد بيمار و افراد سالم از آزمایشگاه جمع آوري گردید.جمعيت مورد مطالعه شامل 25فرد مبتلا به سرطان تخمدان و 25فرد سالم در سنین مختلف بوده است. از روش کیت، برای استخراج DNA ژنومی از خون، استفاده شد. سپس از جایگاه Phe80Val ژن MLH1 جهت بررسی پلی مورفیسم آن با روش ARMS-PCR Tetraاستفاده و همچنین یک جفت پرایمر جهت تایید نهایی تکنیک ARMS-PCR Tetra طراحی گردید.
نتایج: از بین نمونه های مورد بررسی هیچکدام موتاسیونی مشاهده نشد و دو عدد از نمونه ها جهت تعیین توالی به خارج از کشور فرستاده شدند و جایگاه نوکلئوتید بدون هیچ تغییری مشاهده شد.
نتیجه گیری: بطور کلی نتایج تحقیق حاضر نشان داد که هیچگونه ارتباطی بین پلی مورفیسم Phe80Val ژن MLH1 و سرطان تخمدان در نمونه های حاضر وجود نداشت. هرچند نیاز به بررسی روی نمونه های بیشتراز سایر مناطق ایران می باشد.
Background & Aim: Epithelial ovarian cancer accounts for 90% of ovarian malignancies and 25% of gynecologic cancers. Since it is diagnosed late, it has the highest mortality rate among all malignancies of the female reproductive system. Moreover microRNA genes, which regulate gene expression, are observed in ovarian cancer. So, changes in methylation patterns in gene promoter regions are also among the events associated with ovarian cancer.
Materials & Methods: In the present study, samples including normal and cases were collected from hospitals of north of Iran . The samples including twenty five individuals women with ovarian cancer and twenty five individuals women with normal situation in different ages. A commercial kit was used to extract genomic DNA from human blood. The Val80Phe locus of the MLH1 gene was then examined for polymorphism using the Tetra ARMS PCR technique, then for final confirmation of the Tetra ARMS PCR technique, were designed a pair of primers and done PCR sequencing technique.
Results:No mutations were observed between normal and cases. Then two samples were sequenced and no observed single nucleotide polymorphism between them.
Conclusion: Overall, the findings of the present study indicated that there was no association between the MLH1 Val80Phe polymorphism and ovarian cancer in the examined samples. However, further studies on larger sample sizes from other regions of Iran are needed.
1. Flam, F., Einhorn, N., Sjovall Km, (1988), Symptomatology of ovarian cancer. Eur J Gynecol Obstet Reprod Bio. 27:53-7.
2. Stratton, J.F., Thompson, D., Bobrow L., et al. (1999), The genetic epidemiology of early- onset epithelial ovarian cancer: A population- based study Am. J. Hum. Genet. 65: 1725-1732.
3. Goodman, M.T., Howe, H.L., Tung, K.H. et al, (2003), incidence of ovarian cancer by race and ethnicity in the united states, 1992- 1997. Cancer. 97: 26-76.
4. Oscoe Klinck A.B. Lyna Inkel. Genevie`veDufresne-Martin, Julien Gervais-Bird, et al. (2008), Multiple Alternative Splicing Markers for Ovarian Cancer. 68(3): 7-11.
5. Pal, T., Permuth- wey, J., Betts, J.A., et al. (2005), BRCAI and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer, 15(104), 12. 2807- 2816.
6. de Almeida Paiva, V., de Souza Gomes, I., Monteiro, C. R., Mendonça, M. V., Martins, P. M., Santana, C. A., ... & de Azevedo Silveira, S. (2022). Protein structural bioinformatics: An overview. Computers in Biology and Medicine, 147, 105695.
7.Santos, C., Azuara, D., Rodríguez-Moranta, F., & Moreno, V. (2018). MLH1 mutations and chemotherapy resistance in colorectal cancer. Oncotarget, 9(15), 12179–12191.
8. Hamna, L., Adams, M, (2006), Prevention of ovarian cancer best practice and research clinical obstetrics and gynecology. 2: 339-362.
9. Dowty, J.G., Win, A.K., Buchanan, D.D., et al, (2013), Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 34(3):490-7.
10. Holschneider, C.H., Berek, J.S, (2000), Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 19(1): 3-10.
11. Chuchu, Zhao., Saisai, Li., Menghuang, Zhao., Haiyan Zhu and Xueqiong Zhu, (2018), Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy. Arch Gynecol Obstet. 297(1): 153–159.
12. Lin, KM., et al, (1998), Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. 41:428-33.
13. Wagner A, Tops C, Wijnen JT, Zwinderman K, van der Meer C, Kets M, et al.(2002). Genetic testing in hereditary nonpolyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation. J Med Genet . 39:833-37.
14.Valérie Bonadona, Bernard Bonaïti, Sylviane Olschwang, et al, (2011), Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome Article Information JAMA. 305(22):2304-2310.
15. Aquilina G, Ceccotti S, Martinelli S, Soddu S, Crescenzi M, Branch P, Karran P, Bignami M. (2000). Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea. Clin Cancer Res. 6:671–680
16. Scartozzi M, De Nictolis M, Galizia E, Carassai P, Bianchi F, Berardi R, Gesuita R, Piga A, Cellerino R, Porfiri E. (2003). Loss of hMLH1 expression correlates with improved survival in stage III–IV ovarian cancer patients. Eur J Cancer. 39:1144–1149.
17. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M. (1995). Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 55:3721–3725.
18. Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM. (2006). Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer.6:201-208.
19. Ian H, Barry R, Harvey A. Risch, KS, Mario E. Beiner,JM, Ping S, Steven A. (2008). Narod Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1. 109(3): 384–387.
20. Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies & features ofneurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. FamCancer. 2005;4(4):323-33.
21. Scartozzi M, De Nictolis M, Galizia E, Carassai P, Bianchi F, Berardi R, Gesuita R, Piga A, Cellerino R, Porfiri E. (2003). Loss of hMLH1 expression correlates with improved survival in stage III–IV ovarian cancer patients. Eur J Cancer;39:1144–1149.
22. Wagner A, Tops C, Wijnen JT, Zwinderman K, Meer C, Kets M, et al. Genetic testing in hereditary non-polyposis colorectal cancer families with a MSH2, MLH1, or MSH5 mutation. J Med Genet 2002;39:833-37.
23. Stephenson BM, Finan PJ, Gascoyne J, Garbett F, Murday VA, Bishop DT, et al. (1995). Frequency of familial colorectal cancer. Br J Surg. 78:1162-66.